Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Filings indexed 577 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR SIM0613 (LRRC15 ANTIBODY-DRUG CONJUGATE) ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings
2026-05-06 English
Next Day Disclosure Return
Regulatory Filings
2026-05-05 English
Next Day Disclosure Return
Regulatory Filings
2026-05-04 English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION (NDA) OF RADEMIKIBART WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings
2026-04-30 English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2025 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT
Regulatory Filings
2026-04-28 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF ANNUAL REPORT 2025 AND ENVIRONMENT, SOCIAL AND GOVERNANCE REPORT
Report Publication Announcement Classification · 95% confidence The document is a “Notification Letter” to shareholders informing them of the publication of the Annual Report 2025 and the ESG Report on the company’s website, with instructions on how to request printed copies or elect electronic delivery. It does not contain the full annual report itself, but merely announces its availability and directs shareholders to the website. Under the “Menu vs Meal” rule, this is a Report Publication Announcement rather than the report itself.
2026-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.